In sub-Saharan Africa, tuberculosis (TB) case fatality rates of 15%–35% have been reported in HIV-positive TB patients who did not start antiretroviral therapy (ART) during TB treatment.1 Although a number of studies have shown the benefit of the early initiation of ART in co-infected TB patients with low CD4 counts,2–4 there is little evidence to indicate a beneficial effect of ART on TB treatment outcomes in patients with high CD4 counts. Despite this, the WHO and USA HIV treatment guidelines have advised that ART should be started in all HIV-positive TB patients regardless of WHO clinical stage or CD4 count.5,6 In the 2013 WHO treatment guidelines, this is listed as a strong recommendation with low-quality evidence, and in the 2013 USA guidelines it is listed as a strong recommendation with evidence from 1 or more randomized trials.7,8
The references provided by both guidelines are the STRIDE, CAMELIA, and SAPiT studies.2–4,9 Although these studies provided convincing evidence of the need to start ART during TB treatment for patients with low CD4 counts, the STRIDE and CAMELIA studies enrolled patients with a CD4 count less than 250 and 200 cells per cubic millimeter, respectively, whereas the SAPiT study enrolled patients with a CD4 count <500 cells per cubic millimeter and showed a clear survival benefit for patients with CD4 counts <200 cells per cubic millimeter with a trend toward lower mortality in patients with CD4 counts between 200 and 500 cells per cubic millimeter. These studies did not determine an upper CD4 count threshold for the beneficial effect of ART.
Before 2012, the South African ART treatment guidelines recommended the initiation of ART for TB/HIV co-infected patients if they had WHO stage 4 disease or met specified CD4 count criteria, initially <200 cells per cubic millimeter in the 2004 guideline and <350 cells per cubic millimeter in the 2010 guideline.10,11 In 2012, the South African ART program adopted the WHO recommendation that all TB patients should start ART.12
The lowering of the threshold for ART initiation in TB patients is in line with a general international trend to start ART early in HIV disease. The 2013 WHO guidelines recommend the initiation of ART at a CD4 count <500 cells per cubic millimeter, and the 2013 USA Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents advise ART initiation irrespective of CD4 count.6,7 It is still unclear whether these strategies will have a beneficial effect on individual patient outcomes and although they may be easily implemented in well-resourced countries, they may be particularly challenging for low-income countries with a high burden of disease. Data on ART uptake in TB/HIV co-infected patients and its impact on TB case fatality could provide insight on the potential benefit for different patient groups.
In this study, we looked at trends in HIV/TB co-infection and case fatality rates in primary care TB clinics in the City of Cape Town over a 3-year period and ascertained the determinants of mortality in the HIV-positive patients. We also examined ART uptake and the effect of ART on TB case fatality at different CD4 thresholds to determine the potential impact of different ART initiation strategies in this patient population.
In Cape Town, TB treatment is provided to ambulant patients in 101 community clinics run by primary health care nurses and supported by doctors. Forty of these clinics also provide antiretroviral treatment on-site with the remainder referring ART eligible patients to their nearest primary health care ART clinic.
During the period of the study, TB treatment was dispensed according to the South African National TB management guidelines with new patients receiving a treatment regimen comprised of a daily fixed dose combination tablet of rifampicin, isoniazid, pyrazinamide, and ethambutol for a 2-month period, followed by rifampicin and isoniazid for 4 months. Retreatment TB patients were prescribed streptomycin 5 days a week for 2 months, rifampicin, isoniazid, pyrazinamide, and ethambutol daily for 3 months, followed by rifampicin, isoniazid, and ethambutol for a further 5 months.13
Antiretroviral treatment guidelines changed during the 3-year period with regard to both eligibility criteria and treatment regimens. Until mid-2010, adult HIV-positive patients were eligible for ART if they had a CD4 count <200 copies per cubic millimeter or had stage 4 disease. The recommended first-line treatment regimens were d4t or AZT with 3TC and efavirenz or nevirapine.10 In 2010, the new South African ART guidelines extended the CD4 eligibility criteria to <350 cells per cubic millimeter and recommended a first-line regimen of tenofovir, 3TC, and efavirenz.11 Streptomycin and tenofovir were not prescribed together as both drugs are potentially nephrotoxic.14 The second-line ART regimen was comprised of AZT or tenofovir depending on prior exposure during first line plus 3TC and lopinavir/ritonavir. As concomitant use of rifampicin results in lower lopinovir/ritonavir levels, patients on second-line ART had the lopinavir/ritonavir boosted with extra ritonavir or the lopinavir/ritonavir dose doubled slowly over a 3-week period.10,11
All TB cases were notified, and the case details of patients treated in the primary care TB program were routinely entered into a facility-based paper register, which was transcribed into a national electronic TB register (ETR.net) on a quarterly basis.
Included in this analysis were all newly diagnosed adolescent or adult TB patients aged ≥15 years who started TB treatment at one of the primary health care TB clinics in Cape Town between January 01, 2009 and December 31, 2011. Patients who were initiated on treatment in hospital and were referred to a primary care clinic to continue their treatment were included in the analysis; however, to avoid possible duplication of cases, patients who were transferred between primary care clinics were excluded. Also excluded from this study were patients with drug-resistant TB.
This was a retrospective cohort study using an anonymized data set of routine TB program data extracted from the national electronic TB register.
The HIV status of a patient was defined as positive if the patient had a positive HIV test recorded in the database or was registered as receiving ART and/or co-trimoxazole prophylaxis and/or had a recorded CD4 cell count at the start of TB treatment. HIV-negative status was defined by a recorded HIV-negative test result in the database. All other patients were considered to be of unknown HIV status.
TB Case Definitions and Outcomes
TB case definitions and treatment outcomes were recorded in the database according to the internationally recommended WHO case definitions and treatment outcomes of cure, completion, failure, death, default, and transferred out.15 Patients with missing outcomes or more than one outcome were listed as outcome not determined. Case fatality was defined as death during TB treatment. Cause of death was not ascertained.
Descriptive analysis determined trends in annual HIV prevalence, median CD4 counts, ART uptake, and TB treatment outcomes. The CD4 count distribution and case fatality rates by ART status were calculated for the 3-year period. Multivariable Cox proportional hazard models were used to determine risk factors for TB case fatality in the HIV-positive patients. Survival analyses with Kaplan–Meier life tables were used to assess mortality and default risks during TB treatment stratified by ART uptake and CD4 counts at start of TB treatment. Censoring occurred at dates of death, default, transfer out, failure, cure, or completion within a time period of 24 weeks for new patients and 32 weeks for retreatment patients.
Cape Town City Health Directorate approved the use of and provided an anonymized database of routinely collected TB data for this analysis. This study was approved by the University of Cape Town Research Ethics Committee.
From January 01, 2009 to December 31, 2011, 94,593 patients received TB treatment in the primary care TB clinics in the City of Cape Town. Of these, 17,094 were excluded from this analysis as they were under the age of 15 (n = 12,490) or transferred into care (n = 4604). The remaining 77,499 were patients of age ≥15 years who started their TB treatment in one of the 101 primary care TB clinics.
HIV status was determined for 96.5% of all patients treated in the 3-year period. Of these, 50.3% were HIV positive, 46.2% were HIV negative, and the HIV status of 3.4% was unknown. HIV testing increased over the 3-year period with 2.0% of patients recorded as having unknown status in 2011 compared with 5.4% in 2009. There was a small increase in the proportion of HIV-positive patients over the 3 years with 49.7%, 50,4%, and 50,9% recorded as HIV positive in 2009, 2010, and 2011, respectively (P = 0.09).
Baseline Characteristics of the HIV-Positive Patients
The baseline characteristics of the 38,996 HIV-positive TB patients are listed by year of initiation of TB treatment in Table 1. The median age was 34 (interquartile range, 28–40), and 54% of the patients were female. There was an increase in the median CD4 count (interquartile range) from 152 (69–278) in 2009 to 173 (68–305) in 2011 (P < 0.001). The majority of the patients had pulmonary TB (PTB; 75.8%) and were new TB cases (68.5%). The proportion of retreatment cases increased slightly over the 3 years from 30.7% in 2009 to 32.4% in 2011 (P = 0.014). Of the PTB cases, the number of smear negative cases increased from 51.0% in 2009 to 54% in 2011 (P = 0.003). Overall, 92.5% of patients were started on prophylactic co-trimoxazole treatment.
Although the number of co-infected TB patients on ART at TB diagnosis increased over the 3-year period from 9.9% to 12.8% to 17.9% in 2009, 2010, and 2011, respectively, the majority of HIV-positive patients who started TB treatment were ART-naive. ART uptake during TB treatment increased over the study period with 4256 (33.1%), 6207 (47.2%), and 6111 (47.0%) of the HIV-positive patients starting ART during TB treatment in 2009, 2010, and 2011, respectively. Overall, 43%, 60%, and 64.9% of all co-infected patients were on ART at TB diagnosis or started ART during TB treatment in 2009, 2010, and 2011.
TB Treatment Outcomes
Table 2 shows TB treatment outcomes by year for the HIV-positive patients. Overall, cure and completion rates were 75.7% over the 3 years. Case fatality rates declined year on year from 7% to 6.4% to 5.8% in 2009, 2010, and 2011, respectively (P < 0.001). There was no significant change in the default rate (8.7%) over the 3 years. TB treatment outcomes for the HIV-negative patients showed an overall higher cure and completion rate (82.3%) and a lower case fatality rate (3.3%) than the HIV-positive patients. There was also a decrease in case fatality for the HIV-negative patients from 3.7% to 3.3% to 2.9% in 2009, 2010, and 2011, respectively (P = 0.001). The default rate of 8.1% was slightly lower than that of the HIV-positive patients (8.8%) over the 3 years. Treatment failure rates were similar for HIV-positive (2.5%) and HIV-negative patients (2.3%). Case fatality for subgroups of the TB patients is shown in the Supplemental Digital Content (see Table S1, http://links.lww.com/QAI/A527). Case fatality for all HIV-positive patients who started ART was 5% over the 3-year period compared with 8% for patients who did not start ART. In a subgroup of HIV-positive microbiologically confirmed PTB patients who comprised 31% of the HIV-positive cohort, the case fatality rate was 4.8% for the patients who started ART compared with 7.6% for patients who did not.
CD4 Count Distribution
Absolute CD4 counts were available for 95.3% (n = 37,163) of the HIV-positive patients who started TB treatment. Of note is that 33% (n = 12,251) of the patients were severely immune-compromised with CD4 counts <100 cells per cubic millimeter and over 82% (n = 30,492) had CD4 counts <350 cells per cubic millimeter making them eligible for ART based on the 2010 South African National Antiretroviral Guidelines.11 Figure 1A shows uptake of ART by CD4 categories. Over the 3-year period, 35.4% (n = 10,807) of the patients with CD4 counts <350 cells per cubic millimeter did not start ART. Poor uptake of ART was also noted at low CD4 counts with 31.9% (n = 2006) of 6290 patients with a CD4 <50 cells per cubic millimeter not starting ART. Despite improvements in ART uptake over the 3 years, in 2011, 21% of patients with CD4 counts <350 cells per cubic millimeter still did not start ART during TB treatment.
Case Fatality by CD4 Count
Figure 1B shows case fatality rates by CD4 count categories for patients on ART at TB diagnosis (Dx), patients who started ART during TB treatment (Rx), and patients who did not start ART during TB treatment. Although the difference in case fatality between patients on ART and not on ART is most pronounced at low CD4 counts, the positive influence of ART is apparent for all patients with CD4 counts <350 cells per cubic millimeter. Of note is the low case fatality rate for patients with CD4 counts from 350 to 499 cells per cubic millimeter who were not on ART. At 3.2% [95% confidence interval (CI): 2.5% to 3.8%], this is no different to the HIV-negative patients who had a case fatality rate of 3.3% (95% CI: 3.2% to 3.5%) over the 3-year period. It is also not significantly different to the HIV-positive patients who started ART; however, this should be interpreted with caution as patients with CD4 counts >350 cells per cubic millimeter were only eligible for ART in this time period if they had a stage 4 disease. Patients with CD4 counts <350 cells per cubic millimeter had an increased odds of case fatality (odds ratio: 2.4; 95% CI: 2.0% to 2.7%) compared to patients with CD4 counts > 350 cells per cubic millimeter.
Risk Factors for Case Fatality During TB Treatment
In multivariate analysis using Cox proportional hazard models (Table 3), increasing age, female gender, retreatment, and extrapulmonary TB were associated with a higher risk of death during TB treatment. CD4 counts at the start of the TB treatment were most strongly associated with TB case fatality up to a threshold of 350 cells per cubic millimeter. The risk of death for patients with CD4 counts between 200 and 349 cells per cubic millimeter was 1.87 (95% CI: 1.46 to 2.42) compared with patients with CD4 counts ≥500 cells per cubic millimeter (P < 0.001). Although there was a small increase in case fatality for patients with CD4 counts between 350 and 499 cells per cubic millimeter [hazard ratio (HR): 1.19; 95% CI: 0.89 to 1.58] when compared with patients with CD4 counts ≥500 cells per cubic millimeter, this was not statistically significant (P = 0.24).
The risk of death was reduced in patients receiving ART. This reduction was greatest in patients who started ART during TB treatment (HR: 0.42; 95% CI: 0.39 to 0.47) but was also reduced by almost half in patients who were on ART at TB diagnosis (HR: 0.53; 95% CI: 0.39 to 0.47) when compared with patients who did not start ART (P < 0.001).
Figure 2 shows Kaplan–Meier plots of survival and retention in care for the HIV-positive patients. Survival for the HIV-positive patients by CD4 count categories shows significant differences in mortality by CD4 strata in patients with CD4 counts <350 cells per cubic millimeter (log-rank test: P < 0.001). However, there was no difference in mortality by CD4 count strata in patients with CD4 counts >350 cells per cubic millimeter (P = 0.69). The survival analysis by ART status was restricted to patients with CD4 count >350 cells per cubic millimeter and shows improved survival in HIV-positive patients receiving ART (P < 0.001). Patients on ART were also significantly less likely to default TB treatment than patients who did not start ART (P < 0.001). Default rates, however, were not associated with CD4 count (P = 0.21).
This was a large, well-monitored cohort of HIV/TB co-infected patients, with HIV status determined for 96.5% of the patients, CD4 counts available for over 95.3%, and TB treatment outcomes ascertained for 97.5% of the HIV-positive patients.
At 50.3%, the HIV co-infection rate was high; most patients were not on ART, and the median CD4 count at the time of TB diagnosis was low, indicating that the primary care TB service remains an important entry point into antiretroviral treatment. Although there was an increase in ART uptake during the 3-year period and a concomitant decrease in case fatality among the HIV-positive patients, over one-third of the patients with CD4 counts <350 cells per cubic millimeter did not start ART.
The effect of ART on case fatality was most pronounced at low CD4 counts but was apparent at all CD4 count categories <350 cells per cubic millimeter. Although it is difficult to interpret the influence of ART on case fatality above CD4 counts of 350 cells per cubic millimeter because these patients would only have started ART if they had stage 4 disease or other comorbidities, the case fatality rate of 2.5% in patients with CD4 counts >500 cells per cubic millimeter who did not start ART was lower than the case fatality rate of HIV-negative patients (3.3%) and suggests little potential for an additional beneficial effect of ART during TB treatment for this group of patients.
Poor ART uptake and high case fatality rates for HIV-positive patients have been reported in other studies in sub-Saharan Africa. An integrated TB/HIV clinic in Kenya reported an ART uptake of 70% for co-infected TB patients with 13% of patients dying before starting ART and 6% dying while on ART.16 In Malawi, ART uptake was 38% in a cohort of smear-positive PTB patients with a reported case fatality of 3% for patients on ART and 7% for patients not on ART17 and in Zimbabwe, ART uptake was 42% in a cohort of 2655 HIV-positive patients with 14% of patients dying while on ART.17,18
Although ART uptake in our study compares favorably with these cohorts, that over one-third of co-infected TB patients did not access ART confirms that poor ART uptake among TB patients remains an urgent problem. The overall case fatality rate of 6.4% for HIV-positive patients in our cohort was better than many other studies; however, this needs to be interpreted with caution as the treatment location for this study was the primary health care TB service, and it therefore favored ambulant patients and did not include patients who received in-patient treatment. It also excluded patients with drug-resistant TB. These patients were likely to be sicker and have higher case fatality rates. This analysis may therefore be an underestimate of overall TB case fatality in Cape Town.
Although the trend in case fatality on and off ART provides clear evidence of the influence of ART on TB case fatality for different CD4 count categories, this was an observational cohort analysis, and the case fatality data may have been subject to both survival bias and bias by indication. Early mortality during TB treatment could result in survival bias, which could inflate the case fatality rates of patients who did not start ART while bias by indication would result from a clinician's propensity to start the sicker patients on ART and could result in increased case fatality on ART. There were insufficient variables in the routine data for us to adjust the analysis for either of these potential biases.
A further limitation of the study was that the program registered a relatively high default rate. True outcomes for these patients could not be determined, and the default rate may have concealed a higher case fatality rate. However, in contrast to the case fatality analysis, in the default analysis there was no association between default and CD4 count categories for the HIV-positive patients indicating that default was unlikely to be due to unascertained mortality during TB treatment.
As many of the TB clinics did not provide ART, the recording of ART data occurred through patient history for some patients and may not have been as rigorously captured as the TB data. ART data also did not include ART start dates, so although the positive influence of ART on mortality was clearly shown in the multivariate analysis, the influence of the timing of the start of ART could not be determined.
Despite these limitations, this study has provided insight into HIV testing and HIV prevalence rates, the CD4 count distribution, and case fatality in a very large TB treatment program. Because of the comprehensive CD4 data, our study was able to stratify patients both by ART status and CD4 count categories. This provided excellent data on case fatality for patients on and off ART at various CD4 count categories.
This study showed a relatively poor uptake of ART among severely immune-compromised TB patients and a marked survival benefit of ART at low CD4 counts. Patients with CD4 counts <350 cells per cubic millimeter were shown to clearly benefit from ART during TB treatment, and ART initiation should be prioritized for this category of patients. Although this study did not show a decrease in TB case fatality in patients starting ART with CD4 counts >350 cells per cubic millimeter, the duration of the study was restricted to the period of TB treatment, and our findings do not preclude a potential long-term survival benefit of starting all patients on ART during TB treatment.
This study was performed in collaboration with Cape Town City Health Directorate, who provided access to the data they routinely collect to monitor the primary care TB treatment program.
1. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality
rates in high HIV
prevalence populations in sub-Saharan Africa. AIDS. 2001;15:143–152.
2. Havlir DV, Kendall MA, Ive P, et al.. Timing of antiretroviral therapy
-1 infection and tuberculosis
. N Engl J Med. 2011;365:1482–1491.
3. Blanc FX, Sok T, Laureillard D, et al.. Earlier versus later start of antiretroviral therapy
-infected adults with tuberculosis
. N Engl J Med. 2011;365:1471–1481.
4. Abdool Karim SS, Naidoo K, Grobler A, et al.. Timing of initiation of antiretroviral drugs during tuberculosis
therapy. N Engl J Med. 2010;362:697–706.
7. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV
infection, 2013. Available at: www.who.int/hiv/pub/guidelines/arv2013
8. Thompson MA, Aberg JA, Hoy JF, et al.. Antiretroviral treatment of adult HIV
infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308:387–402.
9. Abdool Karim SS, Naidoo K, Grobler A, et al.. Integration of antiretroviral therapy
treatment. N Engl J Med. 2011;365:1492–1501.
14. Kenyon C, Wearne N, Burton R, et al.. The risks of concurrent treatment with tenofovir and aminoglycosides in patients with HIV
. South Afr J HIV
15. World Health Organisation. Treatment of Tuberculosis
: Guidelines—4th ed. Geneva: World Health Organization; 2009.
16. Tayler-Smith K, Zachariah R, Manzi M, et al.. Antiretroviral treatment uptake and attrition among HIV
-positive patients with tuberculosis
in Kibera, Kenya. Trop Med Int Health. 2011;16:1380–1383.
17. Tweya H, Feldacker C, Phiri S, et al.. Comparison of treatment outcomes of new smear-positive pulmonary tuberculosis
patients by HIV
and antiretroviral status in a TB/HIV
clinic, Malawi. PLoS One. 2013;8:e56248.
18. Takarinda KC, Harries AD, Mutasa-Apollo T, et al.. ART uptake, its timing and relation to anti-tuberculosis
treatment outcomes among HIV
-infected TB patients. Public Health Action. 2012;2:50–55.